Subsequent therapy and OS
DISEASE PROGRESSION
Next, 22/31 patients discontinued treatment due to disease progression. Among them, 15 patients accepted subsequent chemotherapy, and seven patients did not accept any subsequent anti‐cancer therapies. In this study, we observed that patients who accepted subsequent chemotherapy had longer OS than those who refused the regimen (18.10 vs. 6.34 months, 